{
    "nct_id": "NCT03648879",
    "official_title": "Phase II Study Evaluating Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome",
    "inclusion_criteria": "* INCLUSION CRITERIA:\n* Patients with Cadherin-1 (CDH1) germline mutation known to be pathogenic or likely pathogenic, which may also be classified as \"significant\" or \"likely significant\" (patients with variants of \"uncertain significance \" are excluded)\n\nor\n\n-Patients with Catenin Alpha 1 (CTNNA1) and partner and localizer of breast cancer 2 (BRCA2) (PALB2) germline mutations suspected to be, or reported to be, associated with hereditary diffuse gastric cancer (HDGC) syndrome.\n\nor\n\n* In the absence of a germline CDH1 mutation, patients must meet clinical criteria for genetic testing due to a history suggestive of Hereditary Diffuse Gastric Cancer (HDGC) syndrome\n* Age greater than or equal to 18 years.\n* Physiologically able to undergo upper endoscopy.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Pregnant women are eligible during second trimester of pregnancy if clinically indicated for evaluation of cancer.\n\nEXCLUSION CRITERIA:\n\n* Current use of therapeutic anticoagulation medication\n* Known bleeding disorder or thrombocytopenia.\n* Unstable angina or recent (within 3 months) myocardial infarction\n* Any clinical contraindication to general anesthesia\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}